A Phase 2 interventional study of SUVN-502 and Placebo in Alzheimer's Disease, sponsored by Suven Life Sciences Limited. Completed at 71 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by Suven Life Sciences Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 166th largest by enrollment of the 1,610 interventional ones that give a count, is one of 72 that started in 2015, is one of 360 in phase 2, and was the 741st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 72 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 564 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Suven Life Sciences Limited has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving donepezil HCl (10 mg qd) and either memantine HCl (10 mg twice daily [bid]) or Namenda XR® (Extended Release, 28 mg qd) or the combination therapy, Namzaric™
The primary objective of the study is to evaluate the efficacy of a serotonin receptor subtype 6 (5-HT6) antagonist, SUVN-502, compared to placebo, as adjunct treatment in subjects with moderate Alzheimer's disease (Mini-Mental State Examination [MMSE] score of 12 to 20) currently treated with the acetylcholinesterase inhibitor, donepezil hydrochloride (HCl), and the N-methyl-D-aspartic acid (NMDA) antagonist, memantine HCl. Efficacy will be assessed by the 11-item Alzheimer's Disease Assessment Scale for Cognitive Behavior (ADAScog-11) after 26 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
Drug: SUVN-502 · Drug: Donepezil · Drug: Memantine
SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
Drug: SUVN-502 · Drug: Donepezil · Drug: Memantine
Placebo adjunct to base treatment with Donepezil and Memantine
Drug: Placebo · Drug: Donepezil · Drug: Memantine
Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)
Mean change from baseline at week 26 is assessed for ADAS-Cog11 score. The ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The scale ranges from 0 to 70, with higher scores indicate greater impairment.
Time frame: Baseline to Week 26
Change From Baseline to Week-26 in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Clinical Dementia Rating-Sum of Boxes (CDR-SB) - Sum of Boxes CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.
Time frame: Baseline to Week 26
Change From Baseline to Week-26 in Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL)
The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score is a 23-item inventory. The ADCS-ADL measures both basic and instrumental activities of daily living The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater disease severity.
Time frame: Baseline to Week 26
Change From Baseline to Week-26 in Neuropsychiatric Inventory (NPI)
Neuropsychiatric Inventory (NPI) 12 item - Total Score NPI assesses psychopathology in participants with dementia and other neurologic disorders. Total score ranges from 12 to 144; higher scores indicate greater disease severity.
Time frame: Baseline to Week 26
Change From Baseline to Week-26 in Change in Mini Mental State Examination (MMSE)
Change in Mini-Mental State Examination (MMSE) - Total Score Minimum Score - 0, Maximum Score - 30. Higher score means better outcome.
Time frame: Baseline to Week 26
Study centers located in the United States of America (USA) participated in the study
| Milestone | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Started | 190 | 185 | 189 |
| Safety population | 187 | 181 | 188 |
| Modified intent-to-treat (mitt) population | 184 | 176 | 183 |
| Completed | 147 | 136 | 157 |
| Not completed | 43 | 49 | 32 |
| Withdrew: Adverse event | 15 | 19 | 10 |
| Withdrew: Lack of efficacy | 5 | 0 | 2 |
| Withdrew: Protocol violation | 4 | 9 | 6 |
| Withdrew: Lost to follow-up | 4 | 4 | 2 |
| Withdrew: Withdrawal by subject | 11 | 9 | 7 |
| Withdrew: Randomized in error and never treated | 4 | 8 | 5 |
Mean change from baseline at week 26 is assessed for ADAS-Cog11 score. The ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The scale ranges from 0 to 70, with higher scores indicate greater impairment.
| score on a scale | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) | 2.0 ± 0.5 | 2.5 ± 0.5 | 2.6 ± 0.5 |
Clinical Dementia Rating-Sum of Boxes (CDR-SB) - Sum of Boxes CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.
| score on a scale | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Change From Baseline to Week-26 in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) | 1.3 ± 0.2 | 1.0 ± 0.2 | 1.2 ± 0.2 |
The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score is a 23-item inventory. The ADCS-ADL measures both basic and instrumental activities of daily living The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater disease severity.
| score on a scale | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Change From Baseline to Week-26 in Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) | -4.6 ± 0.6 | -3.4 ± 0.6 | -4.4 ± 0.6 |
Neuropsychiatric Inventory (NPI) 12 item - Total Score NPI assesses psychopathology in participants with dementia and other neurologic disorders. Total score ranges from 12 to 144; higher scores indicate greater disease severity.
| score on a scale | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Change From Baseline to Week-26 in Neuropsychiatric Inventory (NPI) | 0.5 ± 0.8 | 0.4 ± 0.9 | 2.1 ± 0.8 |
Change in Mini-Mental State Examination (MMSE) - Total Score Minimum Score - 0, Maximum Score - 30. Higher score means better outcome.
| score on a scale | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Change From Baseline to Week-26 in Change in Mini Mental State Examination (MMSE) | -1.1 ± 0.3 | -1.1 ± 0.3 | -1.0 ± 0.3 |
Collected over 26 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SUVN-502 Low Dose (50 mg) | 3/187 (1.6%) | 10/187 (5.3%) | 50/187 (26.7%) |
| SUVN-502 High Dose (100 mg) | 2/181 (1.1%) | 14/181 (7.7%) | 44/181 (24.3%) |
| Placebo | 1/188 (0.5%) | 12/188 (6.4%) | 40/188 (21.3%) |
| Event | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| SyncopeNervous system disorders | 3/187 | 1/181 | 0/188 |
| PneumoniaInfections and infestations | 0/187 | 2/181 | 2/188 |
| Acute kidney injuryRenal and urinary disorders | 0/187 | 2/181 | 0/188 |
| DehydrationMetabolism and nutrition disorders | 2/187 | 0/181 | 0/188 |
| SepsisInfections and infestations | 0/187 | 1/181 | 2/188 |
| Urinary tract infectionInfections and infestations | 0/187 | 1/181 | 0/188 |
| UrosepsisInfections and infestations | 0/187 | 1/181 | 0/188 |
| Haemorrhage intracranialNervous system disorders | 0/187 | 1/181 | 0/188 |
| Acute myocardial infarctionCardiac disorders | 0/187 | 1/181 | 0/188 |
| BradycardiaCardiac disorders | 0/187 | 1/181 | 0/188 |
| Event | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 15/187 | 21/181 | 19/188 |
| HeadacheNervous system disorders | 12/187 | 4/181 | 7/188 |
| DiarrhoeaGastrointestinal disorders | 12/187 | 9/181 | 3/188 |
| FallInjury, poisoning and procedural complications | 11/187 | 10/181 | 11/188 |
A total of 564 patients were randomized as per the planned ratio to receive masupirdine 50 mg (190 patients), masupirdine 100 mg (185 patients), or placebo (189 patients). A total of 543 (96.3%) patients who were randomized to specific treatment sequence were included in the modified intent to treat (mITT) population and this mITT population is considered for baseline analysis.
| Age, Continuous(years) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Mean | 73.4 ± 8.08 | 74.4 ± 6.97 | 72.9 ± 7.23 | 73.6 ± 7.46 |
| Age, Customized(Participants) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Age group greater than or equal to 65 years | 159 | 155 | 157 | 471 |
| Sex: Female, Male(Participants) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Female | 95 | 96 | 106 | 297 |
| Male | 89 | 80 | 77 | 246 |
| Race (NIH/OMB)(Participants) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 3 |
| Asian | 3 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 6 | 8 | 10 | 24 |
| White | 171 | 162 | 168 | 501 |
| More than one race | 3 | 2 | 4 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| APO-E4 Carrier Status(Participants) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Carrier one allele | 77 | 79 | 84 | 240 |
| Carrier two allele | 24 | 31 | 35 | 90 |
| Mini-Mental State Examination(units on a scale) | SUVN-502 Low Dose (50 mg) | SUVN-502 High Dose (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Mean | 16.9 ± 2.21 | 17.0 ± 2.47 | 16.5 ± 2.48 | 16.8 ± 2.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2015, a primary completion of Nov 2019 and a completion of Nov 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2023, 3 years 7 months after primary completion. A results delay was requested in Nov 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suven Life Sciences Limited